Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Beth Israel Deaconess Medical Center
With
Dana-Farber Cancer Institute
Original tumor slides will be collected to identify tumor markers that may predict responses to treatment. Blood samples will be obtained prior to treatment with IL-2.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Malignant melanoma that is metastatic or unresectable
Eligible to receive high-dose IL-2
Tissue block available with adequate tumor to perform RNA extraction and DASL analysis
You may not be if
Prior immunotherapy for unresectable or metastatic disease
Untreated brain metastases, leptomeningeal disease, or seizure disorder
Clareo Health | IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
